Shares of Medidata Solutions Inc (NASDAQ:MDSO) have received a consensus recommendation of “Hold” from the fifteen research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $84.90.
A number of research firms have recently issued reports on MDSO. JPMorgan Chase & Co. began coverage on SEA in a report on Wednesday, June 12th. They issued an “overweight” rating and a $36.00 price objective for the company. Piper Jaffray Companies lowered Medidata Solutions from an “overweight” rating to a “neutral” rating in a research note on Wednesday, June 12th. Wells Fargo & Co reissued a “hold” rating on shares of Medidata Solutions in a research note on Thursday, June 13th. William Blair lowered Medidata Solutions from an “outperform” rating to a “market perform” rating in a research note on Wednesday, June 12th. Finally, SunTrust Banks boosted their target price on Camden Property Trust to $108.00 and gave the company a “buy” rating in a research note on Thursday, June 13th.
In other news, Director Robert Taylor sold 3,294 shares of the business’s stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $90.88, for a total value of $299,358.72. Following the completion of the sale, the director now owns 41,757 shares of the company’s stock, valued at approximately $3,794,876.16. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 4.70% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quadrant Capital Group LLC raised its position in Medidata Solutions by 126.8% during the 1st quarter. Quadrant Capital Group LLC now owns 592 shares of the company’s stock valued at $40,000 after purchasing an additional 331 shares during the last quarter. Bronfman E.L. Rothschild L.P. raised its position in Medidata Solutions by 26.9% during the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 1,286 shares of the company’s stock valued at $87,000 after purchasing an additional 273 shares during the last quarter. Canton Hathaway LLC bought a new position in Medidata Solutions during the 1st quarter valued at approximately $109,000. Advisor Group Inc. raised its position in Medidata Solutions by 27.1% during the 4th quarter. Advisor Group Inc. now owns 2,553 shares of the company’s stock valued at $173,000 after purchasing an additional 545 shares during the last quarter. Finally, World Asset Management Inc purchased a new position in shares of Medidata Solutions during the 1st quarter worth approximately $210,000.
Shares of MDSO traded down $0.02 during midday trading on Tuesday, reaching $90.75. The stock had a trading volume of 848,154 shares, compared to its average volume of 1,674,751. The business has a 50-day moving average price of $91.06. Medidata Solutions has a 12-month low of $60.10 and a 12-month high of $98.60. The company has a quick ratio of 2.57, a current ratio of 2.57 and a debt-to-equity ratio of 0.29. The firm has a market capitalization of $5.65 billion, a P/E ratio of 94.53, a price-to-earnings-growth ratio of 7.40 and a beta of 1.21.
Medidata Solutions (NASDAQ:MDSO) last posted its quarterly earnings data on Tuesday, April 30th. The company reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.33. Medidata Solutions had a return on equity of 9.28% and a net margin of 7.99%. The firm had revenue of $173.50 million during the quarter, compared to analysts’ expectations of $172.12 million. During the same period in the prior year, the business earned $0.40 EPS. The company’s revenue for the quarter was up 16.3% compared to the same quarter last year. As a group, equities analysts forecast that Medidata Solutions will post 0.8 earnings per share for the current fiscal year.
About Medidata Solutions
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development and commercialization of new therapies. The company's platform solutions include data capture and management, and trial planning and management.
Featured Story: What is a short straddle?
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.